Reynders McVeigh Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Reynders McVeigh Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,950	Closed	-$234K	–	201
2015 Q2	$234K	Buy	+1,950	New	+$233K	0.04%	186
2015 Q1	–	Sell	-2,400	Closed	-$233K	–	174
2014 Q4	$233K	Sell	2,400 -700	-23%	-$64.9K	0.04%	156
2014 Q3	$242K	Buy	+3,100	New	+$200K	0.05%	152
2014 Q2	–	Sell	-3,100	Closed	-$208K	–	163
2014 Q1	$208K	Buy	+3,100	New	+$240K	0.05%	158

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Reynders McVeigh Capital Management's ALNY Position: Q3 2015 in Review

Reynders McVeigh Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 1,950 shares — an estimated $234K sold.

Reynders McVeigh Capital Management first reported a position in ALNY in Q1 2014 and held it in 4 quarters. The position peaked at $242K in Q3 2014. 257 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

Reynders McVeigh Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Reynders McVeigh Capital Management sold 1,950 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $234K.
Reynders McVeigh Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Reynders McVeigh Capital Management's Alnylam Pharmaceuticals position peaked at $242K in Q3 2014.
257 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on Reynders McVeigh Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.